November 22nd 2024
A new study shows that COVID-19 infection significantly increases the risk of exacerbation in patients with myasthenia gravis (MG).
There Is No Interaction Between BMI and SGLT2 Inhibitor Efficacy in HF, Review Finds
February 23rd 2024Among patients with heart failure (HF), those taking dapaglifozin or empaglifozin had a 30% odds reduction in HF hospitalization, 14% odds reduction in cardiovascular mortality, and a 10% odds reduction in all-cause mortality compared with patients taking placebo.
Read More
Unlocking T1D Risk: Environmental and Genetic Factors Investigated
February 22nd 2024Outside of genetics, which has a well-documented link to the risk of type 1 diabetes (T1D), investigators detail available research spanning a variety of factors, including viral infections, pesticide exposure, and the gut microbiome.
Read More
Venetoclax Plus HMA Therapy Shows Encouraging Results in Higher-Risk MDS/CMML
February 22nd 2024Results of a phase 1/2 trial show encouraging outcomes for patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) treated with the fully oral regimen of venetoclax and decitabine plus cedazuridine.
Read More
Patients With Early vs Advanced HCC Show Distinct Gut Microbiota Alterations
February 21st 2024Patients with early-stage hepatocellular carcinoma (HCC) and those with advanced-stage disease exhibited distinct gut microbiota diversity and alterations, with future studies warranted to investigate the mechanisms underlying the interactions between gut microbiota and HCC progression.
Read More
Dr Jun Gong: Improved Access Closes the Gaps Between Black, White Men With Prostate Cancer
February 18th 2024Despite socioeconomic and biological differences that contribute to disparities between Black men and White men with prostate cancer, improved access has been shown to reduce the gaps, explained Jun Gong, MD, of Cedars Sinai.
Read More
Experimental RNA Therapy Significantly Reduces Blood Pressure up to 6 Months, Study Says
February 18th 2024Researchers said these findings confirm that zilebesiran can significantly reduce serum angiotensinogen levels, leading to sustained reductions in blood pressure over a 24-hour period, even 6 months post-treatment, though more research is needed for longer-term use.
Read More
Hospitalized Children With Diabetes May Be Able to Continue Safe Use of Home Pumps, Suggest Findings
February 17th 2024Using home insulin pumps when hospitalized was relatively safe compared with hospital-managed pumps and insulin injections among more than 2700 children admitted to a single hospital center.
Read More
Combination Therapies Provide Optimal Hypertensive Control in Patients Taking Ibrutinib
February 17th 2024The retrospective study found patients on Bruton’s tyrosine kinase inhibitors are similar to the general population in the sense that it usually takes at least 2 anti-hypertensive drugs to control blood pressure.
Read More
FDA Grants Accelerated Approval to Lifileucel, First Cellular Therapy for Advanced Melanoma
February 16th 2024Lifileucel was granted approval for the treatment of adults with unresectable or metastatic melanoma that has been previously treated with other therapies, marking the first approval of a tumor-derived cellular therapy in a solid tumor cancer.
Read More
Vyvgart Phase 3 Extension Study Data Affirm Long-Term Safety, Efficacy in gMG
February 15th 2024Details from the final interim data analysis of the ADAPT+ study confirm previous findings seen with efgartigimod (Vyvgart) in generalized myasthenia gravis (gMG), the rare neuromuscular autoimmune disease.
Read More
Nutritional Intervention May Improve Outcomes but Is Underresearched in Ovarian Cancer
February 14th 2024A recent review suggests patients diagnosed with ovarian cancer may benefit from nutritional intervention as part of disease management, but research on the topic has been limited and further investigation is warranted.
Read More
Durvalumab Consolidation Therapy Shows Promise in Elderly Patients With Stage III NSCLC
February 12th 2024Consolidation durvalumab led to comparable outcomes among older patients with unresectable stage III non–small cell lung cancer (NSCLC) vs a younger cohort with the same cancer; this patient population was underrepresented in the PACIFIC trial.
Read More
Dr Chandler Cortina: In Oncology, We Treat the Disease and the Person
February 12th 2024In this interview, Chandler Cortina, MD, MS, FSSO, FACS, Froedtert & the Medical College of Wisconsin, addresses the impact that prioritizing mental health care can have on patients as they navigate through their cancer journey.
Watch
Dr David Eagle: CMS Reimbursement Cuts Encourage Trend of Independent Physician Exodus
February 12th 2024Over the past 20 years, Medicare physician pay has plummeted by 26% when adjusted for inflation, while hospital reimbursement has surged by 70%, prompting over 100,000 doctors to abandon independent practice for hospital or corporate employment since 2019.
Read More